Elicit: CDK4/6 Inhibition in HR+ HER2- Breast Cancer
CDK4/6 Inhibition in HR+ HER2- Breast Cancer
What are the downstream signaling changes and biomarkers of CDK4/6 inhibition in HR+ HER2- breast cancer?
CDK4/6 inhibition induces cell cycle arrest through Rb pathway suppression and E2F downregulation, reduces immunosuppressive cells, and alters growth factor signaling, with key biomarkers including high ER and intact Rb for sensitivity versus IFN pathway activation, Cyclin D1/CDK4 overexpression, and PI3K/mTOR hyperactivation for resistance.
Abstract
CDK4/6 inhibition in HR+ HER2- breast cancer induces multiple downstream signaling changes beyond primary cell cycle arrest. Prevention of Rb phosphorylation leads to G1 arrest and downregulation of E2F-regulated genes including RRM2, TOPO2A, MKI67, MCM7, and CDK2, with treatment shifting tumors from high-risk luminal B to low-risk luminal A molecular phenotype. Growth factor signaling pathways show context-dependent alterations: baseline FGFR2 and ERBB3 expression associate with greater benefit from CDK4/6 inhibition, while acquired PI3K/mTOR hyperactivation drives resistance through Cyclin D1 and CDK4 overexpression. Immune signaling exhibits dual patterns, with beneficial reduction of immunosuppressive Tregs and MDSCs during treatment (p<0.0001) but aberrant IFN/STAT1 pathway activation associated with intrinsic and acquired resistance. Additional changes include suppression of ubiquitin-conjugating enzymes UBE2C, UBE2S, and UBE2T, downregulation of DNA repair pathways in resistant cells, and impairment of radiation-induced ERK and NF-κB/c-Myc signaling.
Methods
We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.
Results
Characteristics of Included Studies
The review included 10 studies investigating downstream signaling changes and biomarkers of CDK4/6 inhibition in HR+ HER2- breast cancer, comprising 3 clinical studies and 7 preclinical studies.
| Study | Full text retrieved? | Study Type | Sample Size/Population | Disease Setting | CDK4/6 Inhibitor Used |
|---|---|---|---|---|---|
| R. Finn et al., 2019 | Yes | Randomized, placebo-controlled, phase III clinical trial | 666 postmenopausal women with HR+/HER2- metastatic breast cancer | Metastatic, treatment-naive | Palbociclib 125 mg daily (3 weeks on, 1 week off) plus letrozole |
| Carmine De Angelis et al., 2021 | No | Preclinical | Cell lines (MCF7, T47D) | Not applicable | Palbociclib |
| Neil A. O’Brien et al., 2018 | Yes | Preclinical | 44 breast cancer cell lines | Not applicable | Abemaciclib (continuous daily, 50 mg/kg) |
| Zijie Cai et al., 2022 | No | Preclinical | Palbociclib-resistant cell lines | Advanced | Palbociclib |
| Chih-Yi Lin et al., 2022 | No | Preclinical | MCF7 and T47D cell lines | Not applicable | Palbociclib, ribociclib, abemaciclib |
| N. Kettner et al., 2019 | No | Preclinical | MCF-7 and T47D cells | Not mentioned | Palbociclib |
| J. G. T. Zañudo et al., 2022 | Yes | Phase I/II clinical trial | 32 female patients, median age 55.5 years | Metastatic HR+ HER2-, pretreated with prior CDK4/6 inhibitors | Palbociclib 100 mg plus everolimus 5 mg plus exemestane 25 mg |
| E. Knudsen & A. Witkiewicz, 2016 | Yes | Preclinical | MCF7 and T47D cell lines, MDA-MB-231 xenograft | Not explicitly stated | Palbociclib (in vitro: 100 nM-1 µM; in vivo: 125 mg/kg) |
| F. Scirocchi et al., 2022 | Yes | Prospective observational study | 50 consecutive women, median age 62 years | Metastatic HR+/HER2-, mostly first-line treatment | Palbociclib, ribociclib, abemaciclib with hormone therapy |
| Wen-Chi Yang et al., 2024 | No | Not mentioned | Not mentioned | Not mentioned | Not specified |
The studies investigated different aspects of CDK4/6 inhibition, including clinical efficacy, resistance mechanisms, downstream signaling pathways, and immune modulation. Three studies used palbociclib exclusively, one used abemaciclib, three tested multiple CDK4/6 inhibitors, and two did not specify the inhibitor. Among clinical studies, one was treatment-naive and one enrolled CDK4/6 inhibitor-pretreated patients.
Downstream Signaling Changes Following CDK4/6 Inhibition
Cell Cycle Pathway Changes
CDK4/6 inhibition consistently affected core cell cycle machinery across studies. The primary mechanism involved prevention of retinoblastoma (Rb) protein hyperphosphorylation, leading to G1 cell cycle arrest. This was accompanied by reduction in cell cycle progression markers including phospho-Rb, TOPOIIa, phosphohistone-H3, and FOXM1. Transcriptional analysis revealed downregulation of E2F-regulated genes including RRM2, TOPO2A, MKI67, MCM7, and CDK2, which tracked with growth inhibitory response.
Growth Factor Signaling Alterations
Multiple growth factor signaling pathways showed altered activity following CDK4/6 inhibition. Tumors with increased expression of FGFR2 and ERBB3 mRNA demonstrated greater PFS gain from palbociclib addition, suggesting interplay between steroid hormone and peptide growth factor signaling drives CDK4/6 dependence.
Immune Signaling Changes
Aberrant interferon (IFN) signaling emerged as a key resistance mechanism. High IFN signaling was associated with reduced CDK4/6 inhibitor sensitivity, with an “IFN-related palbociclib-resistance Signature” (IRPS) derived from transcriptomic analysis.
Biomarker Findings
Predictive Biomarkers of Response and Resistance
Multiple baseline markers showed associations with CDK4/6 inhibitor response. Higher CDK4 levels were associated with endocrine resistance, which was mitigated by palbociclib addition.
Prognostic Biomarkers
Higher ESR1 gene expression was associated with greater benefit from both placebo plus letrozole and palbociclib plus letrozole.
Pharmacodynamic Biomarkers
CDK4 levels showed association with endocrine resistance, suggesting a role in drug activity.
Resistance Mechanisms
Intrinsic Resistance
Approximately 25-35% of patients demonstrated intrinsic resistance to CDK4/6 inhibitors.
Acquired Resistance
Nearly all patients eventually acquired resistance during CDK4/6 inhibitor treatment.
Cross-Resistance Patterns
Palbociclib-resistant cells demonstrated cross-resistance to other CDK4/6 inhibitors and endocrine therapy.
Strategies to Overcome Resistance
Targeting the PI3K/mTOR pathway with specific PI3Kα inhibitor (BYL719) or mTOR inhibitor (everolimus) reduced Cyclin D1 and CDK4 protein levels and restored sensitivity to palbociclib.
Clinical Correlations of Molecular Findings
Response Rates and Molecular Subgroups
The PALOMA-2 trial demonstrated that palbociclib plus letrozole conferred efficacy on both luminal A and B patients, with no single biomarker or cassette of markers associated with lack of benefit from combination treatment.
Progression-Free Survival Associations
Higher CDK4 levels were associated with endocrine resistance and shorter PFS in the placebo arm, with this resistance mitigated by palbociclib.
Immune Correlates of Response
The decrease in Treg levels was significantly greater in responder patients compared to non-responder patients.
Synthesis
The studies revealed substantial mechanistic heterogeneity in CDK4/6 inhibitor response and resistance, requiring synthesis across multiple dimensions to explain divergent findings.